Evaluation of cellular immune response and biosafety of SV40 virus-like particle in tumor immunotherapy
Ting He, Ruoxuan Hei, Chong Liu, Huiping Wang, Zhaowei Gao, Ke Dong, Juan Zhang · 2025
Read Evaluation of cellular immune response and biosafety of SV40 virus-like particle in tumor immunotherapy by Ting He, Ruoxuan Hei, Chong Liu, Huiping Wang, Zhaowei Gao, Ke Dong, Juan Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12783320.txt.
Description
Ting He and co-authors published this immunology study in 2025 on virus-like particles built from the SV40 virus shell. Such particles, empty of genetic material, are promising carriers for vaccines and cancer immunotherapy, but their safety and immune effects inside the body are under-studied. The team injected the particles under the skin of mice and tracked immune cells across key organs.
Imaging showed the particles traveling between lymph nodes. In the spleen they raised the counts of helper T cells and natural killer cells, and helper T cells also rose in gut lymph nodes. Lungs, liver, and kidneys showed no significant changes, and blood chemistry and clotting stayed normal. The particles alone did not treat tumors, but they homed to tumor tissue and raised an inflammatory signal in the spleen. The authors call them a promising, safe platform for further engineering.
Catalog record
| CREATOR | Ting He, Ruoxuan Hei, Chong Liu, Huiping Wang, Zhaowei Gao, Ke Dong, Juan Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |